This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market share, successful commercial execution, or expanded clinical adoption, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
This metric represents the total net sales generated from the Lynozyfic product line within the company's portfolio. It...
Comparable to specific product revenue line items reported by other biopharmaceutical companies, often benchmarked against similar therapeutic class competitors.
regn_segment_lynozyfic_revenues| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $0.00 | $11.20M |